Pharmacogenetics of isoniazid-induced hepatotoxicity

Drug Metabolism Reviews

Volumn 47, Issue 2, 2015, Pages 222-228

  Perwitasari, Dyah Aryani ^a   Atthobari, Jarir ^b   Wilffert, Bob ^c,d  

^a UNIVERSITAS AHMAD DAHLAN   (Indonesia)

^b GADJAH MADA UNIVERSITY   (Indonesia)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Genetic; Hepatotoxicity; Oral antituberculosis; Polymorphism; Tuberculosis

Indexed keywords

ACYLTRANSFERASE; CYTOCHROME P450 2E1; GLUCURONOSYLTRANSFERASE 1A1; GLUTATHIONE TRANSFERASE; ISONIAZID; LEUCINE ZIPPER PROTEIN; NITRIC OXIDE SYNTHASE; URIDINE DIPHOSPHATE; ARYLAMINE ACETYLTRANSFERASE; GLUTATHIONE S-TRANSFERASE M1; GLUTATHIONE S-TRANSFERASE T1; NAT2 PROTEIN, HUMAN; REACTIVE OXYGEN METABOLITE; TUBERCULOSTATIC AGENT;

ENZYME POLYMORPHISM; GENETIC VARIABILITY; HLA SYSTEM; HUMAN; LIVER TOXICITY; PHARMACOGENETICS; REVIEW; DRUG-INDUCED LIVER INJURY; ENZYMOLOGY; GENETICS; METABOLISM;

ANTITUBERCULAR AGENTS; ARYLAMINE N-ACETYLTRANSFERASE; CYTOCHROME P-450 CYP2E1; DRUG-INDUCED LIVER INJURY; GENETIC VARIATION; GLUTATHIONE TRANSFERASE; HUMANS; ISONIAZID; PHARMACOGENETICS; REACTIVE OXYGEN SPECIES;

EID: 84932108291     PISSN: 03602532     EISSN: 10979883     Source Type: Journal    
DOI: 10.3109/03602532.2014.984070     Document Type: Review

References (49)

1. An HR, Wu XQ, Wang ZY, et al. (2012). NAT2 and CYP2E1 polymorphisms associated with antituberculosis drug-induced hepatotoxicity in Chinese patients. Clin Exp Pharmacol Physiol 39: 535-543.
2. Anonymous. (2014). World TB day: Reach the 3 Million. Available from: http://www.who.int/campaigns/tb-day/2014/en/[last accessed 3 May 2014].
3. Babalik A, Arda H, Bakirci N, et al. (2012). Management of and risk factors related to hepatotoxicity during tuberculosis treatment. Tuberk Toraks 60:136-144.
4. Balamurugan A, Sharma SK, Mehra NK. (2004). Human leukocyte antigen class I supertypes influence susceptibility and severity of tuberculosis. J Infect Dis 189:805-811.
5. Bhadauria S, Mishra R, Kanchan R, et al. (2010). Isoniazid-induced apoptosis in HepG2 cells: Generation of oxidative stress and Bcl-2 down-regulation. Toxicol Mech Methods 20:242-251.
6. Bhadauria S, Singh G, Sinha N, Srivastava S. (2007). Isoniazid induces oxidative stress, mitochondrial dysfunction and apoptosis in Hep G2 cells. Cell Mol Biol (Noisy-le-grand) 53:102-114.
7. Boelsterli UA, Lee KK. (2014). Mechanisms of isoniazid-induced idiosyncratic liver injury: Emerging role of mitochondrial stress. J Gastroenterol Hepatol 29:678-687.
8. Brandon EF, Raap CD, Meijerman I, et al. (2003). An update on in vitro test methods in human hepatic drug biotransformation research: Pros and cons. Toxicol Appl Pharmacol 189:233-246.
9. Cai Y, Yi J, Zhou C, Shen X. (2012). Pharmacogenetic study of drugmetabolising enzyme polymorphisms on the risk of anti-Tuberculosis drug-induced liver injury: A meta-Analysis. PLoS One 7:e47769.
10. Chang JC, Liu EH, Lee CN, et al. (2012). UGT1A1 polymorphisms associated with risk of induced liver disorders by anti-Tuberculosis medications. Int J Tuberc Lung Dis 16:376-378.
11. Chowdhury A, Santra A, Bhattacharjee K, et al. (2006). Mitochondrial oxidative stress and permeability transition in isoniazid and rifampicin induced liver injury in mice. J Hepatol 45:117-126.
12. Coomes MW, Prough RA. (1983). The mitochondrial metabolism of 1, 2-disubstituted hydrazines, procarbazine and 1, 2-dimethylhydrazine. Drug Metab Dispos 11:550-555.
13. Du N, Sheng L, Liu Z, et al. (2013). The binding characteristics of isoniazid with copper-zinc superoxide dismutase and its effect on enzymatic activity. Chem Cent J 7:97.
14. Erikson JM, Prough RA. (1986). Oxidative metabolism of some hydrazine derivatives by rat liver and lung tissue fractions. J Biochem Toxicol 1:41-52.
15. Gupta VH, Amarapurkar DN, Singh M, et al. (2013). Association of Nacetyltransferase 2 and cytochrome P450 2E1 gene polymorphisms with antituberculosis drug-induced hepatotoxicity in Western India. J Gastroenterol Hepatol 28:1368-1374.
16. Huang YS. (2007). Genetic polymorphisms of drug-metabolizing enzymes and the susceptibility to antituberculosis drug-induced liver injury. Expert Opin Drug Metab Toxicol 3:1-8.
17. Huang YS. (2014). Recent progress in genetic variation and risk of antituberculosis drug-induced liver injury. J Chin Med Assoc 77: 169-173.
18. Huang YS, Chern HD, Su WJ, et al. (2003). Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 37:924-930.
19. Huang YS, Su WJ, Huang YH, et al. (2007). Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H: Quinone oxidoreductase, glutathione S-Transferase M1 and T1, and the susceptibility to drug-induced liver injury. J Hepatol 47:128-134.
20. Hussain Z, Kar P, Husain SA. (2003). Antituberculosis drug-induced hepatitis: Risk factors, prevention and management. Indian J Exp Biol 41:1226-1232.
21. Jaeschke H, Knight TR, Bajt ML. (2003). The role of oxidant stress and reactive nitrogen species in acetaminophen hepatotoxicity. Toxicol Lett 144:279-288.
22. Lauterburg BH, Smith CV, Todd EL, Mitchell JR. (1985). Pharmacokinetics of the toxic hydrazino metabolites formed from isoniazid in humans. J Pharmacol Exp Ther 235:566-570.
23. Lee SW, Chung LS, Huang HH, et al. (2010). NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-Tuberculosis druginduced hepatitis. Int J Tuberc Lung Dis 14:622-626.
24. Lee WM. (1995). Drug-induced hepatotoxicity. N Engl J Med 333: 1118-1127.
25. Li C, Long J, Hu X, Zhou Y. (2013). GSTM1 and GSTT1 genetic polymorphisms and risk of anti-Tuberculosis drug-induced hepatotoxicity: An updated meta-Analysis. Eur J Clin Microbiol Infect Dis 32: 859-868.
26. Mahapatra S, Woolhiser LK, Lenaerts AJ, et al. (2012). A novel metabolite of antituberculosis therapy demonstrates host activation of isoniazid and formation of the isoniazid-NAD+ adduct. Antimicrob Agents Chemother 56:28-35.
27. Metushi IG, Cai P, Zhu X, et al. (2011). A fresh look at the mechanism of isoniazid-induced hepatotoxicity. Clin Pharmacol Ther 89:911-914.
28. Metushi IG, Sanders C, Lee WM, Uetrecht J. (2014). Detection of antiisoniazid and anti-cytochrome P450 antibodies in patients with isoniazid-induced liver failure. Hepatology 59:1084-1093.
29. Moloney SJ, Guengerich FP, Prough RA. (1985). Propane and propylene formation during the microsomal metabolism of iproniazid and isopropylhydrazine. Life Sci 36:947-954.
30. Nanashima K, Mawatari T, Tahara N, et al. (2012). Genetic variants in antioxidant pathway: Risk factors for hepatotoxicity in tuberculosis patients. Tuberculosis (Edinb) 92:253-259.
31. Oyake T, Itoh K, Motohashi H, et al. (1996). Bach proteins belong to a novel family of BTB-basic leucine zipper transcription factors that interact with MafK and regulate transcription through the NF-E2 site. Mol Cell Biol 16:6083-6095.
32. Peretti E, Karlaganis G, Lauterburg BH. (1987). Acetylation of acetylhydrazine, the toxic metabolite of isoniazid, in humans. Inhibition by concomitant administration of isoniazid. J Pharmacol Exp Ther 243:686-689.
33. Prough RA, Wittkop JA, Reed DJ. (1969). Evidence for the hepatic metabolism of some monoalkylhydrazines. Arch Biochem Biophys 131:369-373.
34. Roy PD, Majumder M, Roy B. (2008). Pharmacogenomics of anti-TB drugs-related hepatotoxicity. Pharmacogenomics 9:311-321.
35. Sharma SK, Balamurugan A, Saha PK, et al. (2002). Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med 166:916-919.
36. Singla N, Gupta D, Birbian N, Singh J. (2014). Association of NAT2, GST and CYP2E1 polymorphisms and anti-Tuberculosis drug-induced hepatotoxicity. Tuberculosis (Edinb) 94:293-298.
37. Sotgiu G, Migliori GB. (2014). Facing multi-drug resistant tuberculosis. Pulm Pharmacol Ther [Epub ahead of print].
38. Spearman ME, Moloney SJ, Prough RA. (1984). Effect of cytosolic components on the metabolism of the hydrazide iproniazid. Mol Pharmacol 26:566-573.
39. Steele MA, Burk RF, DesPrez RM. (1991). Toxic hepatitis with isoniazid and rifampin. A meta-Analysis. Chest 99:465-471.
40. Strange RC, Spiteri MA, Ramachandran S, Fryer AA. (2001). Glutathione-S-Transferase family of enzymes. Mutat Res 482: 21-26.
41. Teixeira RL, Miranda AB, Pacheco AG, et al. (2007). Genetic profile of the arylamine N-Acetyltransferase 2 coding gene among individuals from two different regions of Brazil. Mutat Res 624:31-40.
42. Timbrell JA, Mitchell JR, Snodgrass WR, Nelson SD. (1980). Isoniazid hepatoxicity: The relationship between covalent binding and metabolism in vivo. J Pharmacol Exp Ther 213:364-369.
43. Timperio AM, Rinalducci S, Zolla L. (2005). Hydrazide derivatives produce active oxygen species as hydrazine. Bioorg Chem 33:459-469.
44. Wada M. (2001). Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients. Kekkaku 76:33-43.
45. Wiebkin P, Sieg MS, Nelson RE, et al. (1982). Inhibition of metabolismmediated cytotoxicity by 1, 1-disubstituted hydrazines in mouse mastocytoma (line P815) cells. Biochem Pharmacol 31:2921-2928.
46. Xiang Y, Ma L, Wu W, et al. (2014). The incidence of liver injury in Uyghur patients treated for TB in Xinjiang Uyghur autonomous region, China, and its association with hepatic enzyme polymorphisms nat2, cyp2e1, gstm1 and gstt1. PLoS One 9:e85905.
47. Yamamoto T, Suou T, Hirayama C. (1986). Elevated serum aminotransferase induced by isoniazid in relation to isoniazid acetylator phenotype. Hepatology 6:295-298.
48. Zang Y, Zhao S, Doll MA, et al. (2007). Functional characterization of the A411T (L137F) and G364A (D122N) genetic polymorphisms in human N-Acetyltransferase 2. Pharmacogenet Genomics 17:37-45.
49. Zucker SD, Qin X, Rouster SD, et al. (2001). Mechanism of indinavirinduced hyperbilirubinemia. Proc Natl Acad Sci USA 98: 12671-12676.